[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertrophic-cardiomyopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertrophic-cardiomyopathy":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,41,74,112,164,187,211,233,254,283,306,331,356,386,412,431,452,476,499,522,551,580],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100620720","a-study-to-assess-the-real-world-effectiveness-of-mavacamten-in-adult-patients-with-obstructive-hypertrophic-cardiomyopathy-in-china-100620720",false,"NCT07361289","A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China","A Single-Arm Observational Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China","SOAR-HCM","Inclusion Criteria:\n\n* Participants aged ≥ 18 years (participants enrolled retrospectively: at the time of initial mavacamten prescription), irrespective of gender.\n* Participants who have initiated mavacamten (for whom enrolled retrospectively) or are scheduled to initiate mavacamten (for whom enrolled prospectively) based on clinical therapeutic needs.\n* Diagnosed with obstructive hypertrophic cardiomyopathy (HCM) consistent with current American College of Cardiology Foundation\u002FAmerican Heart Association, European Society of Cardiology, and Chinese guidelines for diagnosis and treatment of patients with hypertrophic cardiomyopathy, i.e., satisfy criteria below:\n\n  * Has a documented diagnosis of HCM prior to enrollment, and\n  * Peak left ventricular outflow tract (LVOT) gradient ≥ 30 mmHg at rest or with provocation in the most recent medical record within 3 months prior to enrollment as assessed by echocardiography.\n* Has documented left ventricular ejection fraction (LVEF) ≥ 55%, as measured by resting transthoracic echocardiography (TTE) in the most recent medical record within 3 months prior to enrollment.\n* New York Heart Association (NYHA) class II or III symptoms in the most recent medical record within 3 months prior to enrollment.\n* For participants enrolled retrospectively, essential baseline information\\* and critical data\\*\\* must be traceable and available. At least one key follow-up time points\\*\\*\\* is required for inclusion.\n\nNote：\n\n\\* Essential baseline information, including age, gender, resting or provoked LVOT peak gradient, LVEF, indices of cardiac structure (e.g., maximum LV wall thickness, atrial and ventricular chamber size and volumes), as well as systolic and diastolic function, NYHA functional class.\n\n* Critical data, including resting or provoked LVOT gradient, LVEF, cardiac structure, systolic and diastolic function, dose of mavacamten.\n\n  * Key follow-up time points: including weeks 4, 8, 12, 24, 36, 48, 72 and 96.\n\n    * Voluntary sign informed consent form. Note: For participants enrolled retrospectively, the most recent medical record within 3 months as mentioned in the above requirements refer to the most recent medical record within 3 months prior to the initial mavacamten prescription.\n\nExclusion Criteria:\n\n* Known HCM phenocopy disease (e.g., Fabry disease, amyloidosis).\n* Participants who are expected to undergo major cardiac surgery during the study.\n* Prior treatment of obstructive HCM with invasive septal reduction (surgical myectomy or percutaneous alcohol septal ablation \\[ASA\\] or septal radiofrequency ablation) within 6 months prior to enrollment (participants enrolled retrospectively: within 6 months prior to initial mavacamten prescription); participants with an unsuccessful myectomy or percutaneous ASA or septal radiofrequency ablation performed \\>6 months prior to enrollment (participants enrolled retrospectively: within 6 months prior to initial mavacamten prescription) may be enrolled.\n* Currently treated with disopyramide or ranolazine (within 14 days prior to enrollment \\[participants enrolled retrospectively: within 14 days prior to initial mavacamten prescription\\]) or participants who are expected to be taking disopyramide, ranolazine, verapamil in combination with β-receptor blockers, or diltiazem in combination with β-receptor blockers during the study.\n* Presence of other diseases that may affect completion of 96 weeks follow-up as assessed by the investigator.\n* Participants who are using or are expected to be using moderate to strong CYP2C19 inhibitors\u002Finducers, or strong CYP3A4 inhibitors, moderate to strong CYP3A4 inducers during the study.\n* Participants who are participating in other interventional clinical studies.","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to assess the effectiveness of mavacamten treatment in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in real-world clinical practice",[25],"Hypertrophic Cardiomyopathy",[27],"Obstructive hypertrophic cardiomyopathy (oHCM)","RECRUITING","2026-06-17",{"date":31,"type":32},"2026-06-18","ACTUAL",{"date":34,"type":32},"2026-01-15",{"date":36,"type":21},"2028-08-28",{"name":38,"class":39},"Bristol-Myers Squibb","INDUSTRY",15,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100242269","pediatric-cardiomyopathy-mutation-analysis-100242269","NCT02432092","Pediatric Cardiomyopathy Mutation Analysis","Inclusion Criteria:\n\n* Subjects with cardiomyopathy\n* Family members of subjects with cardiomyopathy\n\nExclusion Criteria:\n\n* Subjects without cardiomyopathy\n* Family members of subjects without cardiomyopathy",{"count":48,"type":21},300,"The goal of this protocol is to obtain information from individuals with cardiomyopathy and from their families in order to elucidate the molecular genetics of this disorder. This will provide the basis for future genetic counseling as well as contribute to elucidating the biology of normal and abnormal cardiac function.",[51,52,25,53,54,55],"Cardiomyopathies","Dilated Cardiomyopathy","Restrictive Cardiomyopathy","Arrhythmogenic Right Ventricular Cardiomyopathy","Left Ventricular Non-compaction Cardiomyopathy",[57,58,59,60,61,62,63],"Cardiomegaly","Cardiovascular Diseases","Heart Diseases","Systolic dysfunction","Diastolic dysfunction","Ventricular hypertrophy","Heart failure",{"date":65,"type":32},"2026-06-22",{"date":67,"type":4},"2014-04",{"date":69,"type":21},"2030-12-31",{"name":71,"class":72},"Indiana University","OTHER",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":86,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100503515","phase-1-multi-center-open-label-single-ascending-dose-study-of-safety-and-tolerability-of-tn-201-in-adults-with-symptomatic-mybpc3-mutation-associated-hcm-100503515","NCT05836259","Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM","First-in-Human, Open-Label, Safety, Tolerability, Dose-Finding, Pharmacodynamic and Cardiac Transgene Expression Study of TN-201, a Recombinant Adeno-associated Virus Serotype 9 (AAV9) Containing Myosin Binding Protein C Transgene, in Adults With MYBPC3 Mutation-associated Hypertrophic Cardiomyopathy (HCM)","MyPEAK-1","Inclusion Criteria:\n\n* MYBPC3 mutation\n* Hypertrophic Cardiomyopathy (obstructive and nonobstructive)\n* Left Ventricular Ejection Fraction ≥45%\n* NYHA Functional Class II or III symptoms\n* NT-proBNP ≥160pg\u002Fml\n\nExclusion Criteria:\n\n* High AAV9 neutralizing antibody titer","75 Years",{"count":84,"type":21},30,"INTERVENTIONAL",[87,88],"PHASE1","PHASE2","This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyopathy (HCM) caused by mutations in the MYBPC3 gene.",[25],[92,93,94,95,96,97,98,99,100,101],"Hypertrophic Cardiomyopathy (HCM)","Myosin Binding Protein C3 (MYBPC3)","Nonobstructive HCM","Genetic HCM","Familial HCM","Adenoassociated Virus (AAV)","Gene Therapy","Obstructive HCM","nHCM","oHCM","2026-03-18",{"date":104,"type":32},"2026-03-19",{"date":106,"type":32},"2023-08-10",{"date":108,"type":21},"2032-08",{"name":110,"class":39},"Tenaya Therapeutics",10,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":119,"targetDuration":121,"studyType":22,"phases":4,"briefSummary":122,"conditions":123,"keywords":149,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":73},"100560175","institutional-registry-of-rare-diseases-100560175","NCT06573723","Institutional Registry of Rare Diseases","Institutional Registries of Rare Diseases at Hospital Italiano de Buenos Aires (HIBA)","Inclusion Criteria:\n\n* Clinical and\u002For molecular diagnosis of any of the following rare diseases: Amyloidosis, Sarcoidosis, Phacomatosis, Pheochromocytoma, Paraganglioma, Von Hippel-Lindau Disease, Immunoglobulin G4-Related Disease, Demyelinating Diseases, Inborn Errors of Metabolism, Eosinophilic Gastrointestinal Disorders, Hypertrophic Cardiomyopathy, Gaucher Disease, Congenital Adrenal Hyperplasia, Hereditary Angioedema, Pulmonary Hypertension, Wilson Disease, Vascular Anomalies, Mastocytosis, Multiple Endocrine Neoplasia, Inflammatory Bowel Diseases, Prader-Willi Syndrome, Hirschsprung Disease, or Cushing Syndrome.\n* Must be followed at Hospital Italiano de Buenos Aires.\n\nExclusion Criteria:\n\n\\- Refusal to participate in the study or in the informed consent process.",{"count":120,"type":21},380,"10 Years","The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD).\n\nMoreover, the specific goals are to generate an alert system for possible cases of RD with data from the electronic medical record, to describe the occurrence of RD in the evaluated population, to characterize the population, to describe patterns of diagnosis and treatment of RD present at the time, and to explore patient-reported outcomes.",[124,125,126,127,128,129,130,131,132,133,134,25,135,136,137,138,139,140,141,142,143,144,145,146,147,148],"Rare Diseases","Amyloidosis","Sarcoidosis","Phacomatosis","Pheochromocytoma","Paraganglioma","Von Hippel-Lindau Disease","Immunoglobulin G4-Related Disease","Demyelinating Diseases","Inborn Errors of Metabolism","Eosinophilic Gastrointestinal Disorders","Gaucher Disease","Congenital Adrenal Hyperplasia","Hereditary Angioedema","Pulmonary Hypertension","Wilson Disease","Vascular Anomalies","Mastocytosis","Multiple Endocrine Neoplasia","Inflammatory Bowel Diseases","Prader-Willi Syndrome","Hirschsprung Disease","Cushing Syndrome","HHT","Hemorrhagic Hereditary Telangiectasia",[150,151,152,127,153,154,130,131,132,133,134,25,135,136,137,138,139,140,141,142,143,144,145,146,148],"rare diseases","amyloidosis","sarcoidosis","pheochromocytoma","paraganglioma","2026-01-12",{"date":157,"type":32},"2026-01-14",{"date":159,"type":32},"2024-07-01",{"date":161,"type":21},"2034-12-31",{"name":163,"class":72},"Hospital Italiano de Buenos Aires",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":170,"targetDuration":172,"studyType":22,"phases":4,"briefSummary":173,"conditions":174,"keywords":175,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":40},"100544410","austrian-hypertrophic-cardiomyopathy-registry-100544410","NCT06368518","Austrian Hypertrophic Cardiomyopathy Registry","Inclusion Criteria:\n\n* Patients admitted to the HCM outpatient clinic of participating centers of the HCM Registry\n* Interventricular septal thickness ≥ 13 mm and cardiomyopathy-specific red flags OR Interventricular septal thickness ≥ 15 mm not explainable by loading conditions OR Interventricular septal thickness ≥ 17 mm\n* Willingness and ability to provide signed informed consent form (ICF) prior to participation in any study-related procedures\n\nExclusion criteria:\n\n* Age \\\u003C 18 years\n* Known cardiac amyloidosis",{"count":171,"type":21},1000,"20 Years","The Austrian Hypertrophic Cardiomyopathy (HCM) Registry is a prospective, multicenter registry enrolling patients at multiple outpatient clinics across Austria including academic and non-academic centers. Patients will undergo a structured examination process including assessment for symptoms of HCM, past medical history, concomitant medication, family history and the presence of HCM-specific red flags. Furthermore, clinical data derived from electrocardiogram, echocardiography, laboratory analysis, and genetic testing will be collected focusing on a lean variable dictionary and, in addition, specific hypothesis-driven research parameters. All data are entered into an electronic case report form (eCRF) (Phoenix Clinical Trial Management System). In order to perform multicenter analyses, data can be extracted from the eCRF after approval by the steering committee.",[25],[25,176,177],"Left ventricular hypertrophy","Hypertrophic Phenotype","2025-11-27",{"date":180,"type":32},"2025-12-05",{"date":182,"type":32},"2024-03-08",{"date":184,"type":21},"2044-03",{"name":186,"class":72},"Medical University of Graz",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":85,"phases":198,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":73},"100502157","exercise-intolerance-in-non-obstructive-hypertrophic-cardiomyopathy-100502157","NCT05818605","Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy","The EXerCise traIning To rEcovery in HCM Trial","EXCITE-HCM","Inclusion Criteria:\n\n1. Patients 18 to 80 years of age with diagnosis of hypertrophic cardiomyopathy1 defined by left ventricular hypertrophy with end-diastolic wall thickness 15 mm or greater on 2D echocardiography in the absence of other primary causes of left ventricular hypertrophy or wall thickness between 13 and 15 mm in the presence of other features suggestive of hypertrophic cardiomyopathy, such as systolic anterior motion of the mitral valve leaflets, family history of hypertrophic cardiomyopathy, or positive genetic test result.\n2. Left ventricular outflow tract gradient \\\u003C30 mmHg at rest and with provocation.\n3. Left ventricular ejection fraction ≥ 50% by biplane Simpson's method.\n4. Access to exercise equipment at home or at a fitness center.\n5. Ability to complete study related testing including online surveys and smart phone use\n6. Ability to perform 24 weeks of exercise training\n\nExclusion Criteria:\n\n1. History of exercise-induced syncope or ventricular arrhythmias\n2. LVOT obstruction being evaluated for septal reduction therapy; less than 3 months after\n3. History of septal reduction therapy - surgery or ablation\n4. History of ICD placement in the previous 3 months\n5. History of hypotensive response with exercise testing (\\>20 mm Hg decrease of systolic blood pressure from baseline blood pressure or an initial increase in systolic blood pressure followed by a decrease of systolic blood pressure \\>20 mm Hg)\n6. Clinical decompensation in the previous 3 months, defined as New York Heart Association class IV congestive heart failure symptoms or Canadian Cardiovascular Society class IV angina symptoms\n7. Left ventricular ejection fraction less than 50% by echocardiography\n8. Life expectancy less than 12 months\n9. Pregnant or planned pregnancy\n10. Inability to exercise owing to any medical or other limitations\n11. Unwillingness to refrain from competitive sports, burst activity, or heavy isometric exercise for the duration of the study, if assigned to the non-exercise group.","80 Years",{"count":197,"type":21},70,[199],"NA","The EXCITE-HCM study is a randomized, controlled, blinded clinical trial designed to evaluate the effect of moderate intensity exercise training versus usual physicial activity on the improvement of HCM-related symptoms and cardiac function. About 70 participants will be recruited and randomized on a 1:1 ratio to either moderate intensity training or usual physicial activity interventions. Patients will be followed during a period of 24 weeks and assesesments as physical examination, questionnaires, 12 lead ecg's, biomarker levels, echocardiogram, Cardiac Magnetic resonance, PET and CPET will be performed to evaluate their response to the intervention.",[25],"2025-11-19",{"date":204,"type":32},"2025-11-20",{"date":206,"type":32},"2023-02-17",{"date":208,"type":21},"2027-03-01",{"name":210,"class":72},"University of California, San Francisco",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":217,"minAge":218,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":73},"100511458","mavacamten-pregnancy-surveillance-program-100511458","NCT05939700","Mavacamten Pregnancy Surveillance Program","Inclusion Criteria:\n\n* Exposure to at least 1 dose of mavacamten at any time during pregnancy (from 4 months prior to conception to pregnancy outcome) and\u002For at any time during breastfeeding (up to 12 months of infant age or weaning, whichever comes first)\n* At least 15 years of age or older at the time of enrollment\n* Informed consent or institutional review board\u002Fethics committee-approved waiver of informed consent\n\nExclusion Criteria:\n\n\\- None","FEMALE","15 Years",{"count":220,"type":21},20,"The purpose of this observational pregnancy safety study is to assess maternal, fetal, and infant outcomes after exposure to mavacamten at any time during pregnancy and\u002For breastfeeding.",[223,25,224],"Breastfeeding","Pregnancy Related","2025-11-05",{"date":227,"type":32},"2025-11-06",{"date":229,"type":32},"2023-11-09",{"date":231,"type":21},"2027-04-30",{"name":38,"class":39},{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":85,"phases":242,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":73},"100594631","phase-2-a-clinical-study-to-evaluate-the-long-term-safety-of-hrs-1893-in-hypertrophic-cardiomyopathy-100594631","NCT07021963","A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy","A Multicenter, Open-label Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy","Inclusion Criteria:\n\n1. Subjects with hypertrophic cardiomyopathy who have previously completed HRS-1893 related studies.\n2. Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose and must be non-lactating during the study. Female subjects of childbearing potential and male subjects whose partners are women of childbearing potential must agree to refrain from donating sperm\u002Feggs from the time they sign the informed consent form until 3 months after the last dose of trial drug, and to comply with relevant contraceptive requirements.\n3. Understand the study procedures and methods, voluntarily participate in this trial, and sign the informed consent form in writing.\n\nExclusion Criteria:\n\n1. Previous history of coronary artery disease (stenosis of one or more coronary arteries \\>70%) or myocardial infarction.\n2. Have received medication for negative inotropic other than disopyramide, β-blocker, verapamil, diltiazem 4 weeks before screening.\n3. History of syncope or sustained ventricular tachycardia within 6 months prior to screening.\n4. Other conditions that the investigator considers the subject to be unsuitable for participating in this trial, such as physical or psychological diseases or conditions that may increase the risk of the trial, affect the subject's compliance with the protocol, or affect the subject's completion of the trial.","85 Years",{"count":48,"type":21},[88],"This study mainly evaluates the long-term safety of HRS-1893 in subjects with hypertrophic cardiomyopathy.",[25],"2025-09-08",{"date":247,"type":32},"2025-09-10",{"date":249,"type":32},"2025-07-04",{"date":251,"type":21},"2027-12",{"name":253,"class":39},"Shandong Suncadia Medicine Co., Ltd.",{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":261,"sex":17,"minAge":262,"maxAge":263,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":73},"100547562","cardiomyopathies-and-heart-muscle-diseases-cardiac-imaging-in-the-evaluation-of-myocardial-fibrosis-transition-100547562","NCT06409585","Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition","CHIEFTain","Inclusion Criteria:\n\nHFpEF cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Patients with symptomatic heart failure with preserved ejection fraction as defined by the presence of heart failure symptoms (dyspnoea, reduced exercise tolerance, fatigue), signs (elevated jugular venous pressure, pulmonary crackles, peripheral oedema) as well as echocardiographic features (preserved left ventricular systolic function (\\>50%) and reduced diastolic function with septal e' \\\u003C7cm\u002Fs or lateral e' \\\u003C10cm\u002Fs).\n\nHypertrophic cardiomyopathy cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Established diagnosis of hypertrophic cardiomyopathy: left ventricular wall thickness \\>15mm by any imaging modality without a loading condition to explain the hypertrophy OR\n* Left ventricular wall thickness of \\>13 mm by any imaging modality in the presence of a genetic or non-genetic component, supported by other features including family history, non-cardiac symptoms, ECG changes and laboratory tests.\n\nHypertensive heart disease cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of essential hypertension for at least 1 year with evidence of left ventricular hypertrophy on echocardiography (left ventricular mass index \\>98 g\u002Fm2 and relative wall thickness \\>0.42)\n\nArrhythmogenic cardiomyopathy\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of arrhythmogenic right ventricular cardiomyopathy based on the International Task Force 2010 criteria\n\nMyocarditis cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of myocarditis in the past month defined with the following features\n\n  * Chest pain\n  * Evidence of pericarditis (pericardial rub, ST- segment elevation or pericardial effusion)\n  * Elevated serum troponin\n  * Unobstructed coronary arteries on coronary angiogram OR\n  * Cardiac magnetic resonance imaging evidence of myocarditis (subepicardial or mid-wall late gadolinium enhancement\n\nTakotsubo cardiomyopathy cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of takotsubo cardiomyopathy in the past month as defined by European Society of Cardiology guidelines 2018\n\nCardiac sarcoidosis cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of cardiac sarcoidosis for at least 1 year based on expert consensus opinion with\n\n  * Histological diagnosis from a myocardial biopsy OR\n  * Histological diagnosis of extra-cardiac sarcoid AND\n\nOne or more of following is present\n\n* Steroid +\u002F- immunosuppressant responsive cardiomyopathy or heart block\n* Unexplained reduced LVEF (\\\u003C40%)\n* Unexplained sustained (spontaneous or induced) VT\n* Mobitz type II 2nd degree heart block or 3rd degree heart block\n* Patchy uptake on dedicated cardiac PET (in a pattern consistent with CS)\n* Late Gadolinium Enhancement on CMR (in a pattern consistent with CS)\n* Positive gallium uptake (in a pattern consistent with CS) AND\n* Other causes for the cardiac manifestation(s) have been reasonably excluded\n\nExclusion Criteria:\n\n* Inability or unwilling to give informed consent.\n* History of claustrophobia or inability to tolerate supine position for the PET\u002FMR or PET\u002FCT scans.\n* Impaired renal function with eGFR of \\\u003C30 mL\u002Fmin\u002F1.73 m2.\n* Women who are pregnant or breastfeeding.\n* Iodine or gadolinium contrast allergy\n* Contra-indication to CT scanning",true,"30 Years","90 Years",{"count":265,"type":21},290,"Heart scarring, also known as fibrosis, plays a major role in a lot of heart muscle abnormalities. These abnormalities of the heart muscle can lead to major issues such as symptoms of heart failure, dangerous heart rhythm disturbances and even death. However, a lot of these conditions are still not fully understood and treatment options are limited. We here aim to use a new radioactive dye called 68Ga-FAPI to identify patterns and the activity of heart muscle scarring. This radioactive dye is being used in humans particularly in identifying and monitoring cancers and has shown promise in identifying scarring in the heart as well. This will help us not only understand the underlying disease process and risk stratify these patients but also potentially help us develop new targeted therapies that can affect heart muscle scarring. Participants will undergo a baseline MRI scan using this new dye and a plain MRI scan will repeated 12-18 months after to see if there are any changes in the process.",[268,25,269,270,271,272,273],"Heart Failure With Preserved Ejection Fraction","Cardiac Sarcoidosis","Hypertensive Heart Disease","Tako Tsubo Cardiomyopathy","Arrhythmogenic Right Ventricular Cardiomyopathy 1","Myocarditis","2025-08-18",{"date":276,"type":32},"2025-08-19",{"date":278,"type":32},"2023-05-01",{"date":280,"type":21},"2028-01-01",{"name":282,"class":72},"University of Edinburgh",{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":291,"conditions":292,"keywords":293,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":305},"100600866","viz-access-hcm---multi-site-registry-100600866","NCT07103057","VIZ ACCESS HCM - Multi-Site Registry","ACCESS HCM: Real World Evidence for Artificial-Intelligence-assisted Screening and Access to Care for HCM - A Multi-Site Registry","All Cohorts\n\n* Patients aged 18+ years at time of arrival to healthcare facility\n* Patients with a resting 12-lead digital electrocardiogram (ECG) that is flagged by Viz HCM for HCM suspicion\n\nAdditional cohort-specific criteria:\n\nCohort 1 - Newly Diagnosed Patients\n\n* Patients have been diagnosed with HCM after the Viz HCM implementation\n* Written informed consent is obtained prior to data collection\n\nCohort 2 - Previously Diagnosed Patients ● Prior diagnosis of HCM as evidenced by clinical diagnosis documentation prior to Viz HCM implementation\n\nCohort 3 - Suspected and Not Diagnosed Patients\n\n● Patients did not receive sufficient clinical workup for HCM diagnosis confirmation\n\nCohort 4 - Unlikely HCM ● Patient ECG moved to 'Unlikely HCM' group within Viz by site study staff following HCM alert review\n\nCohort 5 - Alerts Not Reviewed\n\n● HCM alert not reviewed by site study staff during study enrollment period",{"count":20,"type":21},"To describe the clinical, economic, and population characteristics of newly diagnosed, previously diagnosed, and suspected patients evaluated by Viz HCM. HCM is underdiagnosed in the community and AI algorithms have been developed as screening tools. However, it is not well understood how to best integrate AI screening tools and their potential impact.",[25],[294,295],"Artificial Intelligence","HCM","2025-08-12",{"date":298,"type":32},"2025-08-17",{"date":300,"type":32},"2025-06-13",{"date":302,"type":21},"2028-12",{"name":304,"class":39},"Viz.ai, Inc.",3,{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":85,"phases":315,"briefSummary":316,"conditions":317,"keywords":318,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":73},"100553758","comparison-of-the-effects-of-inspiratory-muscle-training-and-baduanjin-exercises-in-hypertrophic-cardiomyopathy-patients-100553758","NCT06490250","Comparison of the Effects of Inspiratory Muscle Training and Baduanjin Exercises in Hypertrophic Cardiomyopathy Patients","Comparison of the Effects of Inspiratory Muscle Training and Baduanjin Exercises on Pulmonary Function, Exercise Capacity and Quality of Life in Patients With Hypertrophic Cardiomyopathy","Inclusion Criteria:\n\n* Myocardial thickness in any region of the left ventricle is 15 mm or more on echocardiography or cardiac MRI\n* Clinically and hemodynamically stable (patients with NYHA Class I and II)\n* Patients over 18 years of age\n* Patients who provide informed consent\n\nExclusion Criteria:\n\n* Acute decompensated heart failure\n* Decreased ejection fraction (\\\u003C40%)\n* Unstable angina pectoris\n* Significant coronary artery disease (CAD)\n* Severe renal dysfunction (estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002Fm²)\n* Uncontrolled hypertension (despite medication)\n* Severe valve disease (moderate-severe aortic stenosis, advanced mitral regurgitation)\n* Severe neurological disorders causing autonomic dysfunction\n* Cognitive impairment that prevents communication\n* Recent fractures, osteoporosis, presence of tumors, pregnancy, or back and spine problems",{"count":314,"type":21},51,[199],"The study aims to compare the effects of inspiratory muscle training and Baduanjin exercises on pulmonary function, exercise capacity, and quality of life in patients with hypertrophic cardiomyopathy. By investigating these interventions, the investigators seek to introduce novel approaches that can enhance pulmonary function, exercise capacity, and overall quality of life for these patients.\n\nIn the study, which will involve three groups-the control group, the inspiratory muscle training (IMT) group, and the Baduanjin group-it was calculated that a total of 51 patients, with 17 in each group (n = 17), should be included.\n\nThe IMT group will use an inspiratory muscle training device twice a day, every day of the week, for 15 minutes. This training will continue for 8 weeks, with supervision once a week and unsupervised sessions on the other days.\n\nThe Baduanjin group will participate in a 50-minute exercise program, which includes a 10-minute warm-up, a 30-minute routine of eight separate movements, and a 10-minute cool-down. This will occur three times a week (twice in person and once online) for 8 weeks.",[25,59],[319,320,321],"Exercise capacity","Pulmonary function","Quality of life","2025-06-11",{"date":324,"type":32},"2025-06-15",{"date":326,"type":32},"2024-10-25",{"date":328,"type":21},"2025-11-30",{"name":330,"class":72},"Istanbul University - Cerrahpasa",{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":17,"minAge":339,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":85,"phases":342,"briefSummary":344,"conditions":345,"keywords":4,"overallStatus":346,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":4},"100583246","phase-3-evaluation-of-the-efficacy-and-safety-of-wearable-ecg-at-patch-in-patients-with-hypertrophic-cardiomyopathy-requiring-48-hour-holter-monitoringevaluation-of-the-efficacy-and-safety-of-wearable-ecg-at-patch-in-patients-with-hypertrophic-cardiomyopathy-requiring-48-hour-holter-monitoring-100583246","NCT06873828","Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring","Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring : A Prospective Superiority Study","ATP-HCM","Inclusion Criteria:\n\n1. Male and female subjects aged 19 years or older\n2. Subjects diagnosed with hypertrophic cardiomyopathy who require 48-hour Holter examination\n\nExclusion Criteria:\n\n1. Those judged by the investigator to be unsuitable for this clinical trial or those who may increase the risk due to participation in the clinical trial\n2. Those with sensitive or allergic skin, skin diseases such as skin cancer or rashes\n3. Those with pacemakers, implantable cardioverter-defibrillators, or other implantable electrical devices\n4. Pregnant women","19 Years",{"count":341,"type":21},100,[343],"PHASE3","* Validation of validity, superiority, and safety of data analysis results using AT-Patch compared to 48-hour Holter test results\n* Number of subjects: 100 (including 10% dropout rate)\n* Performance and safety were verified by simultaneously attaching a 48-hour Holter and a wearable Holter device (ATP-C75 or ATP-C135).",[25],"NOT_YET_RECRUITING","2025-03-06",{"date":349,"type":32},"2025-03-13",{"date":351,"type":21},"2025-03",{"date":353,"type":21},"2025-10",{"name":355,"class":72},"Yonsei University",{"id":357,"slug":358,"hasResults":11,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":365,"conditions":366,"keywords":374,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":382,"leadSponsor":384,"locationsCount":73},"100562965","cardiovascular-multimodality-imaging-study-100562965","NCT06610019","Cardiovascular Multimodality Imaging Study","Risk Stratification of Ischemic and Non-ischemic Cardiomyopathies in Racial and Ethnic Minority Groups in the Bronx - Cardiovascular Multimodality Imaging Study","Inclusion Criteria:\n\n* Any adult patient (18 years or older) referred for a cardiovascular magnetic resonance (CMR) imaging study in the Montefiore Health System\n\nExclusion Criteria:\n\n* Any patient who does not meet above criteria",{"count":364,"type":21},5000,"Determining the etiology of cardiomyopathy is of high clinical importance for optimal treatment strategy and prediction of prognosis. There is increased risk for cardiovascular disease and higher propensity for cardiovascular related mortality among Black and non-Hispanic White patients. Recently, advanced cardiac imaging has become a vital tool in diagnosis and risk stratification of cardiovascular disease. Very limited data is available on the prevalence and characteristics of different cardiovascular diseases in Hispanic and African American minority groups, therefore, studying different racial and ethnic minority groups in the Bronx population is an exceptionally valuable source to determine the prevalence of cardiomyopathies among minority groups along with study survival in this population. This study aims to determine the etiology of cardiovascular disease in a diverse patient population by utilizing various cardiovascular imaging modalities, with a focus on cardiac magnetic resonance (CMR) imaging and to develop risk stratification models by applying advanced cardiovascular imaging markers.",[367,51,25,368,369,370,126,371,372,373],"Non-ischemic Cardiomyopathy","Right Ventricular Arrhythmogenic Cardiomyopathy","Cardiac Amyloidosis","Anderson Fabry Disease","Cancer Therapy-related Cardiac Dysfunction","Ventricular Arrythmia","Heart Failure",[375,376,377],"Cardiovascular Mortalities","Cardiomagnetic Resonance (CMR) Imaging","Prospective","2025-02-12",{"date":380,"type":32},"2025-02-14",{"date":278,"type":32},{"date":383,"type":21},"2031-12",{"name":385,"class":72},"Montefiore Medical Center",{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":261,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":73},"100398171","a-10-minute-cardiovascular-magnetic-resonance-protocol-for-cardiac-disease-100398171","NCT04464655","A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease","Healthy Volunteers\n\nInclusion Criteria:\n\n* Age: \\> 18y, Informed consent No known current or pre-existing significant medical conditions that would affect the cardiovascular or respiratory system\n\nExclusion Criteria:\n\n* General MRI contraindications: MR- incompatible devices such as pacemakers, defibrillators, or implanted material or foreign bodies. Consumption of caffeinated drinks or foods (including cocoa and chocolate) during the 12 hours prior to the exam.Regular nicotine consumption during the last 6 months\n\nPatients\n\nInclusion Criteria:\n\n* Age: \\>18 y, Informed consent, Clinically indicated CMR exam\n\nExclusion Criteria:\n\n* General MRI contraindications: MR- incompatible devices such as pacemakers, defibrillators, or implanted material or foreign bodies Vasoactive medication (e.g. nitro) during the 12 hours prior to the exam. Consumption of caffeinated drinks or foods (including cocoa and chocolate) during the 12 hours prior to the exam.\n\nRegular nicotine consumption during the last 6 months",{"count":393,"type":21},2130,"This study aims to identify and assess new CMR techniques that can improve current CMR protocols.",[396,273,397,52,25,398,399,400,401,402],"Coronary Artery Disease","Infiltrative Cardiomyopathy","Aortic Valve Stenosis","Aortic Valve Regurgitation","Pericardial Effusion","Congenital Heart Disease","Vascular Anomaly","2024-10-22",{"date":405,"type":32},"2024-10-24",{"date":407,"type":32},"2019-12-12",{"date":409,"type":21},"2025-01-31",{"name":411,"class":72},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":413,"slug":414,"hasResults":11,"nctId":415,"briefTitle":416,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":11,"sex":17,"minAge":172,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":73},"100545428","taiwan-registry-of-hypertrophic-cardiomyopathy-thic-research-synopsis-100545428","NCT06381778","Taiwan Registry of Hypertrophic Cardiomyopathy (THIC) Research Synopsis","Inclusion Criteria:\n\n1. Presence of left ventricular hypertrophy (LVH) on echo\u002FCMRI:\n2. maximal interventricular septal (IVST) and\u002For posterior wall thickness (PWT) ≥13 mm,\n3. apical wall thickness ≥15 mm or a ratio of apical to basal LV wall thickness of ≥ 1.3 at end-diastole, OR\n4. maximal LV wall thickness ≥ 15mm of ANY OTHER PART\n5. Male and female adult age ≥ 20 year-old\n6. Patients willing to comply with and sign the informed consent\n\nExclusion Criteria:\n\n1. Patients refuse or unable to give informed consent\n2. Patients unlikely to comply with the protocol or unable to understand the nature and possible consequences of the program\n3. Co-arctation of the aorta, severe aortic stenosis, or severe LV pressure overload\n4. Athletic heart\n5. Non-compaction cardiomyopathy",{"count":419,"type":21},2600,"Hypertrophic cardiomyopathy (HCM) is hallmarked by the presence of left ventricular hypertrophy (LVH) and may present various symptoms including arrhythmia and heart failure. Mutations in the genes related to sarcomeric proteins and metabolic disorders are known causes of HCM. However, it remains required to further explore the prevalence of HCM in the context of Taiwanese' genetic background. Additionally, certain rare diseases that affect the heart, including Fabry disease, cardiac amyloidosis, may present LVH, which makes precise diagnosis among HCM and these diseases more challenging. In this TSOC multi-center registry, we aim to systematically evaluate the clinical, genetic, biochemical features,prevalence, and possible natural course of HCM and relevant rare diseases such as Fabry disease in Taiwan. In the meanwhile, we may also generate the specific \"red-flag\" signs of Fabry disease in Taiwan.",[25],"2024-07-24",{"date":424,"type":32},"2024-07-26",{"date":426,"type":32},"2023-02-06",{"date":428,"type":21},"2027-12-01",{"name":430,"class":72},"Far Eastern Memorial Hospital",{"id":432,"slug":433,"hasResults":11,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":439,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":440,"conditions":441,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":451},"100496892","the-smarter-cardiomyopathy-study-100496892","NCT05750147","The SMARTER Cardiomyopathy Study","Genetics, Imaging and Artificial Intelligence for Precision Care in Cardiomyopathy","SMARTER-CM","Inclusion Criteria:\n\nAdults with the capacity to consent Children with parental\u002Fguardian consent Male and Female\n\nMeeting the following criteria:\n\n1. Patients with a confirmed diagnosis of cardiomyopathy or related condition\n2. Patients with a family member with cardiomyopathy, or a related condition\n3. Patients with a genetic variant that may predispose to cardiomyopathy, or a related condition\n\nExclusion Criteria:\n\nPatients without the capacity to provide informed consent",{"count":171,"type":21},"Cardiomyopathies are diseases of the heart muscle. Known genetic factors may account for some cardiomyopathy cases but there is still much to understand about the genetic and environmental causes and how the disease progresses.\n\nFinding new ways to diagnose and treat cardiomyopathies could improve the health and well-being of patients with these conditions.\n\nThis study will collect data from individuals with cardiomyopathy or related heart muscle disease, or with a possible genetic predisposition to cardiomyopathy, and follow them over time to observe the progress of their heart and health. This study will collect DNA, blood samples, and detailed clinical \\& lifestyle information at the start of the study, and data collected during routine healthcare visits over time.\n\n* learn what causes cardiomyopathy, and therefore how to treat it\n* understand why cardiomyopathy progresses differently in different people, to improve the ability to recognise who will benefit from different treatments at different times\n\nThe investigators will collaborate with other centres internationally to collect a large of group of participants with similar cardiomyopathies, providing power to identify new pathways that cause disease and ways of predicting which participants are at risk of having more severe disease.",[51,25,52],"2024-03-05",{"date":444,"type":32},"2024-03-06",{"date":446,"type":32},"2023-03-01",{"date":448,"type":21},"2027-08-01",{"name":450,"class":72},"Imperial College London",2,{"id":453,"slug":454,"hasResults":11,"nctId":455,"briefTitle":456,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":261,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":458,"targetDuration":121,"studyType":22,"phases":4,"briefSummary":460,"conditions":461,"keywords":462,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":73},"100507246","egyptian-hypertrophic-cardiomyopathy-program-100507246","NCT05884892","Egyptian Hypertrophic Cardiomyopathy Program","Inclusion Criteria:\n\n* All patients diagnosed with hypertrophic cardiomyopathy (index patients) who are willing and consented to participate in the registry.\n* All family members of index patients who are willing and consented to participate in the registry.\n\nExclusion Criteria:\n\n* Refusal to consent to participate in the registry program.",{"count":459,"type":21},2000,"Egyptian HCM program aims at defining incidence, severity, phenotype, genotype and determinants of the disease in Egypt, and providing state-of-the-art treatment strategies including medical, surgical and interventional procedures which are patient- and disease-specific.",[25],[295,463,25,464,465,466],"HOCM","Familial Hypertrophic Cardiomyopathy","Hypertrophic Cardiomyopathy with Genetic Marker","Hypertrophic Obstructive Cardiomyopathy","2023-05-23",{"date":469,"type":32},"2023-06-01",{"date":471,"type":32},"2014-01-01",{"date":473,"type":21},"2030-01-01",{"name":475,"class":72},"Magdi Yacoub Heart Foundation",{"id":477,"slug":478,"hasResults":11,"nctId":479,"briefTitle":480,"officialTitle":480,"acronym":481,"eligibilityCriteria":482,"healthyVolunteers":11,"sex":17,"minAge":483,"maxAge":4,"enrollmentInfo":484,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":485,"conditions":486,"keywords":487,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":73},"100350706","optimisation-of-decision-making-for-defibrillator-implantation-in-hypertrophic-cardiomyopathy-100350706","NCT03846297","Optimisation of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy","OPTIM-HCM","Inclusion Criteria:\n\n* Patient with a diagnosis of HCM based on conventional criteria (left ventricle wall thickness ≥ 15 mm in adult index or ≥ 13 mm in adult relatives) in the absence of abnormal loading conditions\n* Aged ≥ 16 years\n* Patient without or with a defibrillator (in this latter case it should have been implanted for primary prevention, not for secondary prevention)\n* Affiliation to a social security insurance\n\nExclusion Criteria:\n\n* Specific etiologies such as amyloidosis\n* Patients with ICD as secondary prevention (after aborted SCD or sustained ventricular arrhythmia)","16 Years",{"count":459,"type":21},"The main objective of the study is to improve implantable cardioverter defibrillator (ICD) implantation decision-making processing relevance by developing a new prediction model of sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM), including newly identified potential biomarkers by magnetic resonance imaging (MRI) and genetics, through a prospective nationwide study, multivariate analysis and modelling of an absolute risk.\n\nThe secondary objective is to perform a medico-economic analysis of ICD implantation in order to define an optimal rule for ICD implantation in patients with HCM, taking into account the benefits of ICD, adverse effects of ICD and associated costs (cost of quality adjusted life years saved).",[25],[488,489],"hypertrophic cardiomyopathy","implantable cardioverter defibrillator","2023-03-15",{"date":492,"type":32},"2023-03-16",{"date":494,"type":32},"2020-09-23",{"date":496,"type":21},"2027-03",{"name":498,"class":72},"Assistance Publique - Hôpitaux de Paris",{"id":500,"slug":501,"hasResults":11,"nctId":502,"briefTitle":503,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":11,"sex":17,"minAge":218,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":508,"conditions":509,"keywords":510,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":520,"locationsCount":73},"100139870","french-hypertrophic-cardiomyopathy-observatory-100139870","NCT01091480","French Hypertrophic Cardiomyopathy Observatory","REMY","Inclusion Criteria:\n\n* Age ≥ 15 years old\n* Patient with HCM defined by an ultrasound thickness of the left ventricle ≥ 13 mm if familial or ≥ 15 mm if sporadic\n\nExclusion Criteria:\n\n* Expressed refusal to participate in the study\n* Significant aortic stenosis (\\\u003C1 cm ²)",{"count":507,"type":21},600,"Hypertrophic cardiomyopathy (Hypertrophic CardioMyopathy=HCM) remains a poorly understood disease with an assumption insufficiently codified. There is no data available in France on the profile of patients, diagnostic methods and assessment and therapeutic use.\n\nThe purpose of this study is to establish a monitoring of patients with HCM (sarcomere of origin or not) in France (diagnosis, treatment)",[25],[511,512,513],"Hypertrophic cardiomyopathy","Observatory","LVH","2022-09-20",{"date":516,"type":32},"2022-09-21",{"date":518,"type":32},"2010-01",{"date":302,"type":21},{"name":521,"class":72},"French Cardiology Society",{"id":523,"slug":524,"hasResults":11,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":528,"eligibilityCriteria":529,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":530,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":532,"conditions":533,"keywords":536,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":73},"100313569","evaluation-of-heart-involvement-in-patients-with-fabry-disease-100313569","NCT03362164","Evaluation of HEArt invoLvement in Patients With FABRY Disease","Prospective Monocentric Cohort Study to Evaluate Predictors for Heart Failure and Sudden Cardiac Death in Patients With Fabry Disease","HEAL-FABRY","Inclusion Criteria:\n\n* Fabry disease (genetically confirmed)\n* Signed informed consent\n* 18 years and older\n\nExclusion Criteria:\n\n* No informed consent\n* Withdrawal of informed consent",{"count":531,"type":21},650,"This study evaluates predictors for the incidence of arrhythmias and sudden cardiac death as well as terminal heart failure in patients with Fabry disease.",[124,534,535,25],"Fabry Disease","Fabry Disease, Cardiac Variant",[537,538,539,540,541],"Fabry","Fibrosis","Dialysis","Stroke","Chronic kidney disease","2022-07-06",{"date":544,"type":32},"2022-07-07",{"date":546,"type":32},"2001-01",{"date":548,"type":21},"2032-03",{"name":550,"class":72},"Wuerzburg University Hospital",{"id":552,"slug":553,"hasResults":11,"nctId":554,"briefTitle":555,"officialTitle":556,"acronym":557,"eligibilityCriteria":558,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":559,"targetDuration":561,"studyType":22,"phases":4,"briefSummary":562,"conditions":563,"keywords":567,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":578,"locationsCount":73},"100445490","stress-echo-2030-the-novel-abcde-fglpr-protocol-to-define-the-future-of-imaging-100445490","NCT05081115","Stress Echo 2030: the Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging","The International Stress Echo Study to to Define the Future of Imaging","SE2030","Inclusion Criteria:\n\nKnown or suspected coronary artery disease Hypertrofic cardiomiopathy Repaired Tetralogy of Fallot Primary valvular disease\n\nExclusion Criteria:\n\n\\-",{"count":560,"type":21},10000,"5 Years","With stress echo (SE) 2020 study, a new standard of practice in stress imaging was developed and disseminated: the ABCDE protocol for functional testing within and beyond CAD. ABCDE protocol was the fruit of SE 2020, and is the seed of SE 2030, which is articulated in 12 projects: 1-SE in coronary artery disease (SECAD); 2- SE in diastolic heart failure (SEDIA); 3-SE in hypertrophic cardiomyopathy (SEHCA); 4- SE post-chest radiotherapy and chemotherapy (SERA); 5- Artificial intelligence SE evaluation (AI-SEE); 6- Environmental stress echocardiography and air pollution (ESTER); 7- SE in repaired Tetralogy of Fallot (SETOF) ; 8- SE in post-COVID-19 (SECOV); 9: Recovery by stress echo of conventionally unfit donor good hearts (RESURGE); 10- SE for mitral ischemic regurgitation (SEMIR); 11- SE in valvular heart disease (SEVA); 12- SE for coronary vasospasm (SESPASM). The study aims to recruit in the next 5 years (2021-2025) ≥10 000 patients followed for ≥5 years (up to 2030) from ≥20 quality-controlled laboratories from ≥10 countries. In this COVID-19 era of sustainable health care delivery, SE2030 will provide the evidence to finally recommend SE as the optimal and versatile imaging modality for functional testing anywhere, any time and in any patient.",[396,373,25,401,564,565,566],"Valvular Heart Disease","Post-chest Radio\u002FChemiotherapy","Heart Transplantation",[568,569,570,571],"effectiveness","registry","stress echo","sustainability","2021-10-18",{"date":574,"type":32},"2021-10-26",{"date":576,"type":32},"2021-04-01",{"date":69,"type":21},{"name":579,"class":72},"Fatebenefratelli Hospital",{"id":581,"slug":582,"hasResults":11,"nctId":583,"briefTitle":584,"officialTitle":584,"acronym":585,"eligibilityCriteria":586,"healthyVolunteers":261,"sex":17,"minAge":483,"maxAge":263,"enrollmentInfo":587,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":588,"conditions":589,"keywords":592,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":73},"100270765","molecular-and-imaging-studies-of-cardiovascular-health-and-disease-100270765","NCT02804269","Molecular and Imaging Studies of Cardiovascular Health and Disease","Biobank","There is no inclusion\u002Fexclusion criteria except for the age limit as this is a repository program.\n\nInclusion Criteria:\n\n•Subject aged ≥ 16 years and ≤ 90 years.\n\nExclusion Criteria:\n\n•No",{"count":364,"type":21},"Biobank is a program which collects biological samples, health information and imaging data from consented patients and stored them at the core facility. These information would be used to study the molecular, imaging and outcome studies of cardiovascular health and disease.",[590,52,25,591],"Healthy","Ischemic Heart Disease",[593,594,511,595,596],"Healthy Volunteer","Dilated cardiomyopathy","ischemic heart disease","Cardiovascular Magnetic Resonance Imaging","2016-06-14",{"date":599,"type":21},"2016-06-17",{"date":601,"type":4},"2013-07",{"date":603,"type":21},"2033-07",{"name":605,"class":72},"National Heart Centre Singapore"]